CD8A and pancreatic neoplasm: It was found that the proportion of CD3+ T, CD4+ T and CD8+ T in pancreatic cancer did not change significantly (Fig. 1D, E), and there was no significant difference in the expression level of GzmB in CD8+ T after the deletion of GPR116 receptor (Fig. 1G).